IRONWOOD PHARMA INC CLASS A (IRWD)
Sector: Health Care
2026 Annual Meeting Analysis
IRONWOOD PHARMA INC CLASS A · Meeting: June 16, 2026
Directors FOR
0
Directors AGAINST
8
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Dr. Currie has served since 2019 and Ironwood's stock has lost roughly 60% of its value over three years, falling 73 percentage points behind the XBI biotech ETF benchmark — far exceeding the 30-point gap that triggers a vote against, and the five-year record shows no improvement.
Dr. Denner has served since 2020 and his tenure substantially overlaps the three-year period in which Ironwood's stock fell approximately 60%, trailing the XBI biotech ETF by 73 percentage points — well beyond the 30-point trigger — and the five-year record does not provide a mitigating offset.
Mr. Duane has served since 2019 and Ironwood's stock has declined roughly 60% over three years, trailing the XBI biotech ETF by 73 percentage points — far exceeding the 30-point threshold for companies with negative absolute returns — with the five-year record showing continued underperformance.
Ms. Kessler has served since 2019 and Ironwood's stock has lost roughly 60% over three years, trailing the XBI biotech ETF by 73 percentage points — well beyond the 30-point trigger applicable to companies with negative absolute returns — with no five-year mitigant available.
Mr. McCourt has served as CEO and director since June 2021, a tenure that substantially overlaps the period in which Ironwood's stock fell roughly 60%, trailing the XBI biotech ETF by 73 percentage points — far exceeding the 30-point trigger — and the five-year record does not provide a mitigating offset; as an executive director, he is subject to the same performance trigger as independent directors.
Ms. McHugh has served as board chair since 2014 and her lengthy tenure fully covers the three-year period in which Ironwood's stock declined roughly 60%, trailing the XBI biotech ETF by 73 percentage points — far exceeding the 30-point trigger — and the five-year record confirms this is not a temporary trough.
Ms. Moukheibir has served since 2019 and Ironwood's stock has lost roughly 60% over three years, trailing the XBI biotech ETF by 73 percentage points — well beyond the 30-point trigger for companies with negative absolute returns — with no improvement over the five-year window.
Mr. Shepard has served since 2020 and his tenure substantially overlaps the three-year period in which Ironwood's stock fell roughly 60%, trailing the XBI biotech ETF by 73 percentage points — far exceeding the 30-point trigger — and the five-year record does not mitigate the underperformance.
For Analysis
All eight director nominees are recommended AGAINST. Ironwood's three-year stock return of approximately -60% trails the XBI biotech ETF by 73 percentage points, far exceeding the 30-point trigger applicable to companies with negative absolute returns. No director benefits from the 24-month new-director exemption, and the five-year return of approximately -63% confirms sustained underperformance rather than a transient trough, eliminating the 5-year mitigant. The 1-year rebound (+333%) is noted but does not alter the 3-year or 5-year trigger analysis under policy.
Say on Pay
✓ FORCEO
Thomas McCourt
Total Comp
$1,948,390
Prior Support
96%%
CEO Thomas McCourt received total compensation of approximately $1.95 million in 2025, which is modest for a CEO of a publicly traded biotech company at Ironwood's market cap and well within reasonable benchmark ranges; the compensation program emphasizes variable pay through performance stock awards tied to relative total shareholder return over a three-year period, and fixed salary represents a minority of total pay, satisfying the pay-mix requirement. Prior-year say-on-pay support was approximately 96%, reflecting strong shareholder alignment, and while the stock has underperformed, the compensation level itself is not above-benchmark and the incentive structure includes meaningful performance conditions that already punished executives — the 2023 relative TSR performance awards paid out at zero.
Auditor Ratification
✓ FORAuditor
KPMG LLP
Tenure
N/A
Audit Fees
$1,300,000
Non-Audit Fees
$455,811
KPMG's non-audit fees (tax services of $455,811) represent approximately 35% of audit fees ($1,300,000), which is well below the 50% threshold that would raise independence concerns; KPMG tenure is not disclosed in the filing so no tenure trigger fires, and there is no evidence of material restatements attributable to audit failure.
Actual Vote Results
8-K filed June 18, 2026
Other Proposals
Proposal 1
Amendment to Amended and Restated 2019 Equity Incentive Plan to increase shares available for issuance by 10,000,000 shares of Class A common stock
Overall Assessment
The 2026 Ironwood Pharmaceuticals annual meeting presents four proposals; all eight director nominees are recommended AGAINST due to sustained stock underperformance of approximately 60% over three years, trailing the XBI biotech ETF by 73 percentage points with no five-year mitigant available. The auditor ratification and say-on-pay proposals both pass policy screens and are recommended FOR, while the equity plan amendment falls outside the scope of this policy.